Performance evaluation of affinity column mediated immunometric assay for tacrolimus

Korean Journal of Laboratory Medicine

Volumn 29, Issue 5, 2009, Pages 415-422

  Chung, Jae Woo ^a   An, Dongheui ^a   Song, Junghan ^b   Chung, Hee Jung ^a   Park, Hae Il ^c   Lee, Woochang ^a   Chun, Sail ^a   Min, Won Ki ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Affinity column mediated immunometric assay; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

BILIRUBIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

AFFINITY CHROMATOGRAPHY; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD; CHEMISTRY; CHYLE; DRUG MONITORING; EVALUATION; HUMAN; IMMUNOASSAY; METHODOLOGY; REPRODUCIBILITY; STATISTICAL PARAMETERS;

BILIRUBIN; CHROMATOGRAPHY, AFFINITY; CHYLE; DRUG MONITORING; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; LIMIT OF DETECTION; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 77949322521     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2009.29.5.415     Document Type: Article

References (27)

1. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995;17:606-14.
2. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-94.
3. Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994;344: 883.
4. Westley IS, Taylor PJ, Salm P, Morris RG. Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients. Ther Drug Monit 2007;29:584-91.
5. Ghoshal AK and Soldin SJ. Evaluation of the Dade Behring Dimension RxL: integrated chemistry system-pediatric reference ranges. Clin Chim Acta 2003;331:135-46.
6. Keown PA. New concepts in cyclosporine monitoring. Curr Opin Nephrol Hypertens 2002;11:619-26.
7. Kuzuya T, Ogura Y, Motegi Y, Moriyama N, Nabeshima T. Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay. Ther Drug Monit 2002;24:507-11.
8. LeGatt DF, Shalapay CE, Cheng SB. The EMIT 2000 tacrolimus assay: an application protocol for the Beckman Synchron LX20 PRO analyzer. Clin Biochem 2004;37:1022-30.
9. Napoli KL. Is microparticle enzyme-linked immunoassay (MEIA) reliable for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant recipients. Ther Drug Monit 2006;28:491-504.
10. Taylor PJ and Morris RG. Tacrolimus measurement by microparticle enzyme immunoassay II. Ther Drug Monit 2003;25:259-60.
11. CSM-B surveys: Immunosuppressive drugs participant summary report, AACC/CAP 2007.
12. CSM-A surveys: Immunosuppressive drugs participant summary report, AACC/CAP 2007.
13. Kim JH, Kim BK, Lee SY, Chun S, Kwon GC, Yoon Y, et al. Annual report on external quality assessment in therapeutic drug monitoring in Korea (2006). J Lab Med Qual Assur 2007;29:121-35. (Korean Source (2006). Korean Source 2007;29:121-35.).
14. Clinical and Laboratory Standard Institute. Evaluation of the precision performance of clinical chemistry devices; approved guidelinesecond edition (EP5-A2). Wayne, PA: Clinical and Laboratory Standards Institute, 2004.
15. Clinical and Laboratory Standard Institute. Evaluation of the linearity of quantitative measurement procedures: A statistical approach; approved guideline (EP6-A). Wayne, PA: Clinical and Laboratory Standards Institute, 2003.
16. Kroll MH, Praestgaard J, Michaliszyn E, Styer PE. Evaluation of the extent of nonlinearity in reportable range studies. Arch Pathol Lab Med 2000;124:1331-8.
17. Clinical and Laboratory Standard Institute. Protocols for determination of limits of detection and limits of quantitation; approved guideline (EP17-A). Wayne, PA: Clinical and Laboratory Standards Institute, 2004.
18. Westgard JO. Method validation-the detection limit experiment. http://www.westgard.com/lesson29.htm (Updated on Jun 2009).
19. Clinical and Laboratory Standard Institute. Method comparison and bias estimation using patient samples; approved guideline-second edition (EP9-A2). Wayne, PA: Clinical and Laboratory Standards Institute, 2002.
20. Clinical and Laboratory Standard Institute. Interference testing in clinical chemistry; approved guideline-second edition (EP7-A2). Wayne, PA: Clinical and Laboratory Standards Institute, 2005.
21. Guidance for Industry Bioanalytical Method Validation. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed September 2009).
22. Dorizzi RM, Cocco C, Rizzotti P. Tacrolimus assays; new tools for new tests and for old problems. Clin Chim Acta 2008;387:177-8.
23. Griffey MA, Hock KG, Kilgore DC, Wei TQ, Duh SH, Christenson R, et al. Performance of a no-pretreatment tacrolimus assay on the Dade Behring Dimension RxL clinical chemistry analyzer. Clin Chim Acta 2007;384:48-51.
24. Cogill JL, Taylor PJ, Westley IS, Morris RG, Lynch SV, Johnson AG. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 1998; 44:1942-6.
25. Iwasaki K, Shiraga T, Matsuda H, Nagase K, Tokuma Y, Hata T, et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 1995;23:28-34.
26. Ghoshal AK and Soldin SJ. IMx tacrolimus II assay: is it reliable at low blood concentrations? A comparison with tandem MS/MS. Clin Biochem 2002;35:389-92.
27. Tomita T, Homma M, Yuzawa K, Ohkohchi N, Hori T, Kaneko M, et al. Effects of hematocrit value on microparticle enzyme immunoassay of tacrolimus concentration in therapeutic drug monitoring. Ther Drug Monit 2005;27:94-7.